The global non-invasive cancer diagnosis market is anticipated to grow at a CAGR of 7.2% during the forecast period. A non-invasive cancer diagnosis is a method of detecting cancer conditions with just a small incision in the body. Rising chronic cancers with growing demand for minimally invasive diagnostics are driving the non-invasive cancer diagnostics market across the globe. According to WHO, around 10 million deaths occurred due to cancer in 2020. The most common new cases of cancer in 2020 include breast cancer (2.26 million), lung cancer (2.21 million), colon and rectum cancer (1.93 million), prostate cancer (1.41 million), stomach cancer (1.09 million), and others. This significant number of cancer cases has shifted the global attention towards the adoption of early detection and diagnosis techniques for cancer.

Additionally, the growing awareness programs, increasing healthcare expenditure, and initiatives by government and healthcare organizations are boosting the market growth across the globe. Cancer Research UK, the Department of Health, NHS England, and Public Health England in collaboration has launched National Awareness and Early Diagnosis Initiative (NAEDI) in 2007.  The initiative aims to raise cancer awareness among the public and medical professionals, as well as to encourage early detection. A growing number of such initiatives are raising awareness of cancer diagnosis and treatment among global patients. However, the high cost of treatment and stringent regulatory guidelines are the factors that are hindering the growth of the non-invasive cancer diagnosis market during the forecast period. 

Impact of COVID-19 Pandemic on Global Non-Invasive Cancer Diagnosis Market

The global non-invasive cancer diagnosis market is hit by the outbreak of COVID-19 since December 2019 as the emergence of healthcare announced by WHO. Initially in Italy, screening for cancers was forcefully suspended. The non-invasive cancer diagnosis market has declined especially in the first half of 2020.  The outbreak of COVID-19 has disrupted the supply of raw materials and products across the globe. As doctors frontline warriors fighting against COVID-19, all other treatment procedures were postponed except emergency cases. The COVID-19 pandemic shows severe symptoms in people, who are already suffering from chronic disease. This has impacted that people did not visit the hospital not to get exposed to the virus. To fight the pandemic the key players were focusing on the manufacturing of chemicals for sanitizers, and also donated methylene diphenyl diisocyanate (MDI) to enable the manufacture of prefabricated polyurethane insulation panels for hospital construction and other materials to manufacture personal protective equipment (PPE) for medical personnel fighting the coronavirus. The market will witness “V” shape recovery in near future owing to the restart of key industries in major economies. 

Segmental Outlook 

The global non-invasive cancer diagnosis market is segmented based on type, and techniques. Based on the type, the market is segmented into blood cancer, breast cancer, solid tumors, lung cancer, and others. Due to the rapid rise in the number of breast cancer cases across the globe, breast cancer accounted for one of the largest shares of the non-invasive cancer diagnostic market in 2020. Based on the techniques, the market is segmented into clinical chemistry, immunochemistry/immunoassay, molecular diagnostics, and other clinical instruments. 

Global Non-Invasive Cancer Diagnosis Market Share by Techniques, 2020 (%)

Breast Cancer Segment projected to hold the significant share in the global non-invasive cancer diagnosis Market

Among the techniques for the non-invasive cancer diagnosis market, the breast cancer segment held the highest share in 2020 and is also anticipated to grow during the forecast period. The increasing number of breast cancer across the globe is driving the growth of the market. For instance, according to the World Health Organization, in 2020, there were around 2.3 million women diagnosed with breast cancer, and 685,000 have died across the globe. 

Regional Outlooks

The global non-invasive cancer diagnosis market is further segmented based on geography including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, and Others0, and the Rest of the World (the Middle East and Africa, and Latin America).  North America has been predicted to dominate the global non-invasive cancer diagnosis market due to well-established health infrastructure, development in technology, support from the government, and the high prevalence of these cancer cases among people. For instance, as per the American Society of Clinical Oncology (ASCO), in 2020 around 49,290 women were diagnosed with non-invasive breast cancer in the US. Rising awareness in people towards early diagnosis for cancer and well-structured reimbursement policies in the region are driving the market. 

Global Non-Invasive Cancer Diagnosis Market Growth, by Region 2021-2027

Asia-Pacific is projected to have a considerable growth in the global Non-Invasive Cancer Diagnosis market

Asia-Pacific is anticipated to hold a considerable growth in the global non-invasive cancer diagnosis market. The increasing prevalence of cancer patients and rising awareness about minimal invasive equipment for diagnosis are the major factors that are driving the growth of the market during the forecast period. For instance, as per the Organization for economic corporation and development, in 2018, around 839,000 women were diagnosed with breast cancer and more than 286,000 died of the disease in the region. Further, the government initiatives for the healthcare diagnosis and technology advancement in creatin opportunity for the market during the forecast period. The developing economies such as China and India with increasing tourism will also fuel the market growth. 

Market Players Outlook

The key players of the non-invasive cancer diagnosis market include A&G Pharmaceutical Inc., BioVie Inc., Laboratory Corporation of America, LungLife AI, Inc., Novartis AG, GE Healthcare, AVIVA Biosciences Corp., Quest Diagnostics Inc., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in September 2020, LabCorp., a life science company focused on patient care decisions, has launched a non-invasive test for patients with non-small cell lung cancer (NSCLC). Resolution ctDx Lung is a fast liquid biopsy test that was developed and will be run by Resolution Bioscience.

The Report Covers

• Market value data analysis of 2020 and forecast to 2027.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global non-invasive cancer diagnosis market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.